Last reviewed · How we verify

Intravenous levetiracetam

Muhammad Aamir Latif · Phase 2 active Small molecule

Intravenous levetiracetam is a Small molecule drug developed by Muhammad Aamir Latif. It is currently in Phase 2 development. Also known as: injection Levera, Keppra.

At a glance

Generic nameIntravenous levetiracetam
Also known asinjection Levera, Keppra
SponsorMuhammad Aamir Latif
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intravenous levetiracetam

What is Intravenous levetiracetam?

Intravenous levetiracetam is a Small molecule drug developed by Muhammad Aamir Latif.

Who makes Intravenous levetiracetam?

Intravenous levetiracetam is developed by Muhammad Aamir Latif (see full Muhammad Aamir Latif pipeline at /company/muhammad-aamir-latif).

Is Intravenous levetiracetam also known as anything else?

Intravenous levetiracetam is also known as injection Levera, Keppra.

What development phase is Intravenous levetiracetam in?

Intravenous levetiracetam is in Phase 2.

Related